Meriofert

Follicle‑Stimulating Hormone; Luteinising Hormone, the active ingredient in Meriofert, is a gonadotropin (biologic) presented as a biologic injectable for intramuscular or subcutaneous use. It treats infertility caused by anovulation and is employed in controlled ovarian stimulation for assisted reproductive technologies. It is indicated for women undergoing fertility treatment cycles.

GNH USA supplies Meriofert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Meriofert is a gonadotropin used in reproductive medicine to stimulate ovarian follicle development.

Anovulatory infertility: promotes follicular growth to enable ovulation Controlled ovarian stimulation for IVF: enhances multiple follicle development for egg retrieval Assisted reproductive technology cycles: improves ovarian response to achieve higher success rates Ovarian stimulation in intrauterine insemination (IUI): increases number of mature oocytes Ovulation induction in polycystic ovary syndrome (PCOS): facilitates regular ovulation

Meriofert may be associated with a range of adverse reactions following injection.

Common Side Effects: - Injection site pain: mild discomfort at the injection site. - Bruising or hematoma: localized bleeding under the skin. - Abdominal discomfort: mild pelvic pain or bloating. - Nausea: transient feeling of sickness. - Headache: mild to moderate tension‑type headache. - Mild ovarian hyperstimulation syndrome: mild abdominal distension and weight gain.

Serious or Rare Side Effects: - Severe ovarian hyperstimulation syndrome: rapid weight gain, ascites, respiratory distress. - Multiple pregnancy: increased risk of twins or higher‑order gestations. - Allergic reaction or anaphylaxis: rash, itching, swelling, difficulty breathing. - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Ectopic pregnancy: implantation outside the uterine cavity.

When using Meriofert, clinicians should observe several precautionary measures to minimise risks. - Monitor ovarian response: perform serial ultrasound and estradiol measurements. - Avoid in patients with ovarian cysts or tumors: risk of exacerbation. - Use caution in hypersensitive individuals: discontinue if allergic signs appear. - Assess pregnancy status: not indicated for use during established pregnancy. - Discuss risk of multiple gestation: counsel patients on potential outcomes. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meriofert can interact with other medications that affect ovarian stimulation or hormonal balance.

Major Interactions (Avoid): - GnRH agonists: may cause excessive ovarian stimulation when combined. - Estrogen‑containing contraceptives: reduce the efficacy of Meriofert. - Thyroid hormone therapy: altered response may occur. - Anticoagulants: increased risk of ovarian bleeding.

Moderate Interactions (Monitor Closely): - Clomiphene citrate: additive stimulation may increase OHSS risk. - Letrozole: may enhance follicular response, requiring dose adjustment. - Metformin: can modify ovarian sensitivity in PCOS patients. - Other gonadotropins: cumulative effect may lead to over‑stimulation.